Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy
Open accessThe DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.
Abstract
Enhancer of zeste homolog 2-mediated (EZH2-mediated) epigenetic regulation of T cell differentiation and Treg function has been described previously; however, the role of EZH2 in T cell-mediated antitumor immunity, especially in the context of immune checkpoint therapy, is not understood. Here, we showed that genetic depletion of EZH2 in Tregs (FoxP3creEZH2fl/fl mice) leads to robust antitumor immunity. In addition, pharmacological inhibition of EZH2 in human T cells using CPI-1205 elicited phenotypic and functional alterations of the Tregs and enhanced cytotoxic activity of Teffs. We observed that ipilimumab (anti-CTLA-4) increased EZH2 expression in peripheral T cells from treated patients. We hypothesized that inhibition of EZH2 expression in T cells would increase the effectiveness of anti-CTLA-4 therapy, which we tested in murine models. Collectively, our data demonstrated that modulating EZH2 expression in T cells can improve antitumor responses elicited by anti-CTLA-4 therapy, which provides a strong rationale for a combination trial of CPI-1205 plus ipilimumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“It was demonstrated that ipilimumab induces the expression of EZH2, a key epigenetic enzyme that plays an important role in cellular plasticity (115-118).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [116]
In the citing paper
“The combination of EZH2 inhibition with anti-CTLA4 therapy led to improved survival in the preclinical studies (116).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [116]
In the citing paper
“On the basis of these observations, a series of preclinical studies were designed that identified a potential role for EZH2 in driving adaptive resistance to anti-CTLA4 therapy.”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [116]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775 · cited 1×
“EZH2 is a catalytic subunit of polycomb repressive complex 2 (PRC2) that trimethylates lysine 27 on histone H3 (H3K27me3), leading to gene repression (2, 3).”
BackgroundThe Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347 · cited 1×
“EZH2 is a catalytic subunit of polycomb repressive complex 2 (PRC2) that trimethylates lysine 27 on histone H3 (H3K27me3), leading to gene repression (2, 3).”
BackgroundZhou, X., Bailey-Bucktrout, S. L., Jeker, L. T., Penaranda, C., Martínez-Llordella, M., Ashby, M., Nakayama, M., Rosenthal, W., & Bluestone, J. A. (2009) · Nature Immunology · doi:10.1038/ni.1774 · Cited by 1,370 · cited 1×
“CPI-1205–treated Tregs seem to acquire the phenotype of so-called exFoxP3 cells, which were previously shown to have an activated memory phenotype (19).”
BackgroundEpigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201 · cited 1×
“As EZH2 regulates expression of Th-1 chemokines such as CXCL9 and CXCL10 in the tumor cells (14), we performed in vitro (cell line) and in vivo (murine tumor model) experiments to assess the contribution of CXCL9 and CXCL10 in our system.”
MethodWei, G., Wei, L., Zhu, J., Zang, C., Hu-Li, J., Yao, Z., Cui, K., Kanno, Y., Roh, T.-Y., Watford, W. T., et al. (2009) · Immunity · doi:10.1016/j.immuni.2008.12.009 · Cited by 1,152
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
Overacre-Delgoffe, A. E., Chikina, M., Dadey, R. E., Yano, H., Brunazzi, E. A., Shayan, G., Horne, W., Moskovitz, J. M., Kolls, J. K., Sander, C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.005 · Cited by 627
Stability and function of regulatory T cells is maintained by a neuropilin-1–semaphorin-4a axis
Delgoffe, G. M., Woo, S.-R., Turnis, M. E., Gravano, D. M., Guy, C., Overacre, A. E., Bettini, M. L., Vogel, P., Finkelstein, D., Bonnevier, J., et al. (2013) · Nature · doi:10.1038/nature12428 · Cited by 587
BACH2 represses effector programs to stabilize Treg-mediated immune homeostasis
Roychoudhuri, R., Hirahara, K., Mousavi, K., Clever, D., Klebanoff, C. A., Bonelli, M., Sciumè, G., Zare, H., Vahedi, G., Dema, B., et al. (2013) · Nature · doi:10.1038/nature12199 · Cited by 407
Kanno, Y., Vahedi, G., Hirahara, K., Singleton, K., & O'Shea, J. J. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075058 · Cited by 342
DuPage, M., Chopra, G., Quiros, J., Rosenthal, W. L., Morar, M. M., Holohan, D., Zhang, R., Turka, L., Marson, A., & Bluestone, J. A. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.007 · Cited by 332 · cited 2×
“org Volume 128 Number 9 September 2018 Introduction Enhancer of zeste homolog 2 (EZH2) is expressed in T cells following its activation via CD28 signaling (1).”
Background
Cited by
Items 101–200 of 245
Serganova, I. S., Chakraborty, S., Yamshon, S., Isshiki, Y., Bucktrout, R., Melnick, A. M., Béguelin, W., & Zappasodi, R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.805195 · Cited by 31
“Notably, CTLA-4 blockade with ipilimumab was found to increase EZH2 expression in T cells, including Tregs, and EZH2 inhibition was shown to improve the therapeutic response to anti–CTLA-4 through modulation of the Treg phenotype (Goswami et al., 2018; Wang et al., 2018).”
BackgroundThe epigenetic landscape of fate decisions in T cells
Jay, A., Pondevida, C. M., & Vahedi, G. (2025) · Nature Immunology · doi:10.1038/s41590-025-02113-x · Cited by 35
“In CD8 + T cells, DNMT and EZH2 inhibitors have been used to improve antitumor immunity by blocking the deposition of epigenetic marks at memory and proliferation-associated genes such as Tcf7 , Bcl6 , Lef1 and Il7r 129–131 .”
Meddens, C., van der List, A. C. J., Nieuwenhuis, E. E. S., & Mokrý, M. (2019) · Gut · doi:10.1136/gutjnl-2018-317516 · Cited by 35
Qiu, J., Sharma, S., Rollins, R. A., & Paul, T. A. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0072 · Cited by 31
Targeting the Tumor-Tumor Microenvironment Crosstalk
Badve, S., & Gökmen‐Polar, Y. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2230362 · Cited by 28
Lawton, M. L., Inge, M. M., Blum, B. C., Smith-Mahoney, E. L., Bolzan, D., Lin, W., McConney, C., Porter, J., Moore, J., Youssef, A., et al. (2024) · PLoS Biology · doi:10.1371/journal.pbio.3002943 · Cited by 27
Omar, H. A., & Tolba, M. F. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.01.009 · Cited by 32
BMI1 maintains the Treg epigenomic landscape to prevent inflammatory bowel disease
Gonzalez, M. M., Bamidele, A. O., Svingen, P. A., Sagstetter, M. R., Smyrk, T. C., Gaballa, J. M., Hamdan, F. H., Kosinsky, R. L., Gibbons, H. R., Sun, Z., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140755 · Cited by 31
“1172/JCI140755 2 expressing T cell (16, 20, 25, 33).”
Chemical biology and pharmacology of histone lysine methylation inhibitors
Barghout, S. H., Machado, R. A. C., & Baršytė-Lovejoy, D. (2022) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2022.194840 · Cited by 34
Watanabe, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105352 · Cited by 31
“Blockade of CTLA-4 signaling enhanced EZH2 expression in human CD4+ effector T cells and CD8+ T cells and Tregs, whereas EZH2 inhibition improves response to anti-CTLA-4 via modulation of cytotoxic effector T cells and altering the Treg phenotype into effector-like T cell profile [91].”
BackgroundRole of heterogeneous regulatory T cells in the tumor microenvironment
Wei, T., Zhong, W., & Li, Q. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104659 · Cited by 28
New Therapeutic Options for Advanced Hepatocellular Carcinoma
Ma, Y., Liu, J., Wu, T., & Fu, D. (2020) · Cancer Control · doi:10.1177/1073274820945975 · Cited by 29
“Specific knockout or blocking of CTLA-4 can activate the autoimmune response and improve anticancer immunity.(116) In 2011, the US FDA approved a randomized phase III clinical trial using the monoclonal antibody ipilimumab blocking CTLA-4 for the treatment of melanoma.”
BackgroundEpigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential
Maes, K., Mondino, A., Lasarte, J. J., Agirre, X., Vanderkerken, K., Prósper, F., & Breckpot, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652160 · Cited by 26
Mola, S., Pinton, G., Erreni, M., Corazzari, M., Andrea, M. D., Grolla, A. A., Martini, V., Moro, L., & Porta, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094391 · Cited by 29
“Therefore, EZH2 inhibition alone or in combination with immune checkpoints has been found to be associated with enhanced CD8 T cell infiltration and antitumor immunity [23,24,61,62].”
BackgroundBlake, M. K., O’Connell, P. M., & Aldhamen, Y. A. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1082195 · Cited by 29
“Dissecting the dominant role of EZH2 in T cells in the TME is complicated by the above-mentioned pleotropic effects of this chromatin modifier, and also the fact that most studies on EZH2 have been performed in mice.”
BackgroundInfluentialCancer epigenetic therapy: recent advances, challenges, and emerging opportunities
Vatapalli, R. J., Rossi, A. P., Chan, H. M., & Zhang, J. (2024) · Epigenomics · doi:10.1080/17501911.2024.2430169 · Cited by 31
The functions of EZH2 in immune cells: Principles for novel immunotherapies
Shao, F.-F., Chen, B.-J., & Wu, G. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.1ru0520-311r · Cited by 26
RKIP Pleiotropic Activities in Cancer and Inflammatory Diseases: Role in Immunity
Touboul, R., Baritaki, S., Zaravinos, A., & Bonavida, B. (2021) · Cancers · doi:10.3390/cancers13246247 · Cited by 25
Lineage Reprogramming of Effector Regulatory T Cells in Cancer
Dixon, M. L., Leavenworth, J. D., & Leavenworth, J. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.717421 · Cited by 23
“Similarly, disruption of Ezh2 activity or depletion of Helios in Tregs leads to Foxp3 instability with an increased expression of effector cytokines like IFNg and TNFa, enhanced anti-tumor immunity, and decreased tumor growth and progression (54, 55, 88).”
BackgroundInfluentialZhang, X., Huo, X., Guo, H., & Xue, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.965244 · Cited by 28
Elrakaybi, A., Ruess, D. A., Lübbert, M., Quante, M., & Becker, H. (2022) · Cancers · doi:10.3390/cancers14235926 · Cited by 25
Tumor microenvironment and immunotherapy: from bench to bedside
Sinha, A., Ghosh, D., & Karati, D. (2025) · Medical Oncology · doi:10.1007/s12032-025-02818-x · Cited by 25
“Combination treatment may increase the medicinal efficiency of antibodies targeting CTLA-4 and reduce the quantity of immune compromised cells [95].”
EZH2 regulatory roles in cancer immunity and immunotherapy
Mortezaee, K. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155992 · Cited by 23
Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer
Shin, D. S., Park, K., Garon, E. B., & Dubinett, S. M. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.06.005 · Cited by 20
Fischetti, I., Botti, L., Sulsenti, R., Cancila, V., Enriquez, C., Ferri, R., Bregni, M., Crivelli, F., Tripodo, C., Colombo, M. P., et al. (2024) · Epigenomics · doi:10.2217/epi-2023-0374 · Cited by 24
“In several preclinical tumor models EZH2 genetic or pharmacologic inhibition induced recruitment and cytokine production of effector T cells, and skewed Treg toward pro-inflammatory functions [21–23] .”
BackgroundTargeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer
Jama, M., Tabana, Y., & Barakat, K. (2024) · European journal of medical research · doi:10.1186/s40001-024-01901-9 · Cited by 23
“EZH2 inhibition in combination with anti-CTLA-4 mAB enhanced the antitumor immune response in murine models, as evidenced by the increased ratio of Treg to T effector cells and enhanced cytotoxicity of T effector cells compared to anti-CTLA-4 monotherapy [31].”
BackgroundWestaby, D., Viscuse, P. V., Ravilla, R., de la Maza, M. D. F., Hahn, A. W., Sharp, A., Bono, J. S. D., Aparicio, A. M., & Fleming, M. T. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321209 · Cited by 22
Targeting the spectrum of immune checkpoints in prostate cancer
Sena, L. A., Denmeade, S. R., & Antonarakis, E. S. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1949287 · Cited by 20
McGoverne, I., Dunn, J., Batham, J., Tu, W. J., Chrisp, J. S., & Rao, S. (2020) · BMC Immunology · doi:10.1186/s12865-020-00353-0 · Cited by 19
Heidari‐Foroozan, M., Rezalotfi, A., & Rezaei, N. (2024) · International Reviews of Immunology · doi:10.1080/08830185.2024.2401352 · Cited by 19
“Conversely, its inhibition increases the production of anti-cancer chemokines CXCL9 and CXCL10 leading to a more robust anti-tumor immunity [139,140].”
Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy
Singh, V., Nandi, S., Ghosh, A., Adhikary, S., Mukherjee, S., Roy, S., & Das, C. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10167-w · Cited by 23
“Beyond its role in combination with anti-PD-1 therapy, the implications of EZH2 modulation have also been explored in conjunction with anti-CTLA-4 therapy [134].”
InfluentialLSD1 inhibition improves efficacy of adoptive T cell therapy by enhancing CD8+ T cell responsiveness
Pallavicini, I., Frasconi, T. M., Catozzi, C., Ceccacci, E., Tiberti, S., Haas, D., Samson, J., Heuser-Loy, C., Lauson, C. B. N., Mangione, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51500-9 · Cited by 23
“This paves the way for a new generation of immunotherapies.”
Zhang, B., Ma, Z., Tan, B., & Lin, N. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1559824 · Cited by 22
“Enhancer of zeste homolog 2 (EZH2), which is a lysine N-methyltransferase, is known to regulate the methylation of H3K27 and results in transcriptional repression of target genes [75].”
BackgroundPace, L. (2021) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a037754 · Cited by 20
Single cell suppression profiling of human regulatory T cells
Søndergaard, J. N., Tulyeu, J., Priest, D., Sakaguchi, S., & Wing, J. B. (2025) · Nature Communications · doi:10.1038/s41467-024-55746-1 · Cited by 18
Epi‐Immunotherapy in Cancer Treatment: Mechanisms, Clinical Progress, and Future Directions
Lu, N., Rong, G., & Han, W. (2025) · Cancer Innovation · doi:10.1002/cai2.70023 · Cited by 19
“Consistent with these findings, studies in mouse models have shown that EZH2 gene knockdown in Tregs produces antitumor effects [99].”
Histone methyltransferase Ezh2 negatively regulates NK cell terminal maturation and function
Yu, M., Su, Z., Huang, X., Zhou, Y., Zhang, X., Wang, B., Wang, Z., Liu, Y., Xing, N., Xia, M., et al. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.1ma0321-155rr · Cited by 17
Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects
Huang, R., Wu, Y., & Zou, Z. (2022) · Epigenomics · doi:10.2217/epi-2022-0320 · Cited by 19
Epigenetic modulations of immune cells: from normal development to tumor progression
Xu, Y., He, Z., Du, J., Chen, K., Creemers, J. W. M., Wang, B., Fan, L., & Wang, Y. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.88327 · Cited by 23
“Consistently, Goswami et al. reported that inhibition of EZH2 increases infiltration of Th1 cells and cytotoxic effector T cells in the TME as well as a depletion of Tregs in bladder cancer murine model (116).”
BackgroundNew insights into the basic biology of acute graft-versus-host-disease
Li, A. H., Abraham, C., Wang, Y., & Zhang, Y. (2020) · Haematologica · doi:10.3324/haematol.2019.240291 · Cited by 19
Sylvestre, M., Tarte, K., & Roulois, D. (2019) · Epigenomics · doi:10.2217/epi-2019-0165 · Cited by 19
Pauken, K. E., Alhalabi, O., Goswami, S., & Sharma, P. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.005 · Cited by 22
The pleiotropic roles of EZH2 in T-cell immunity and immunotherapy
Wang, Y., Bui, T., & Zhang, Y. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03466-x · Cited by 19
“Modulating Tregs using an EZH2 inhibitor improved anti-tumor responses elicited by anti-CTLA-4 therapy [84].”
BackgroundPromising therapy for neuroendocrine prostate cancer: current status and future directions
Xin, F., Xue, J.-W., Wu, J.-Z., Yang, C., Wang, K., & Ma, Q. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241269676 · Cited by 18
Barili, V., Vecchi, A. L., Rossi, M., Montali, I., Tiezzi, C., Penna, A., Laccabue, D., Missale, G., Fisicaro, P., & Boni, C. (2021) · Cells · doi:10.3390/cells10102563 · Cited by 22
Exploring oncogenic roles and clinical significance of EZH2: focus on non-canonical activities
Woźniak, M., & Czyż, M. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241306026 · Cited by 21
Palicelli, A., Croci, S., Bisagni, A., Zanetti, E., de Biase, D., Melli, B., Sanguedolce, F., Ragazzi, M., Zanelli, M., Chaux, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212314 · Cited by 18
“It also increased the intratumoral trafficking of activated CD8+ T cells and M1 TAMs, overall reversing the resistance to anti-PD-1 inhibitors.”
BackgroundInfluentialDrugging the Epigenome: Overcoming Resistance to Targeted and Immunotherapies in Melanoma
Hanly, A. M., Gibson, F. T., Nocco, S. E., Rogers, S., Wu, M., & Alani, R. M. (2021) · JID Innovations · doi:10.1016/j.xjidi.2021.100090 · Cited by 19
Zhang, B., Tan, H., Kuang, J., Zhou, B., Liang, S., Pang, X. Y., Ouyang, Y., Zhang, Z., Long, Y., & Zhang, H. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02487-4 · Cited by 17
“This provides a robust theoretical foundation for combining EZH2 inhibitors with anti-CTLA-4 treatment [175].”
EZH1/2 Inhibitors Favor ILC3 Development from Human HSPC-CD34+ Cells
Damele, L., Amaro, A., Serio, A., Luchetti, S., Pfeffer, U., Mingari, M., & Vitale, C. (2021) · Cancers · doi:10.3390/cancers13020319 · Cited by 10
“The development of novel and promising therapeutic approaches in solid tumors, such as epigenetic DNA targeting, has prompted scientists to extensively evaluate the effects of these approaches on the restoring/impairing of T cell-mediated anti-tumor responses [15,16,71,72], while there are still limited data on their…”
BackgroundMultiomics characteristics and immunotherapeutic potential of EZH2 in pan-cancer
Luo, L., Wang, Z., Hu, T., Feng, Z., Zeng, Q., Shu, X., Wu, A., Huang, P., Cao, Y., Tu, Y., et al. (2023) · Bioscience Reports · doi:10.1042/bsr20222230 · Cited by 16
lncRNAs-EZH2 interaction as promising therapeutic target in cutaneous melanoma
Woźniak, M., & Czyż, M. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1170026 · Cited by 16
“Downregulation of EZH2 in TILs via EZH2 small-molecule inhibitor CPI-1205 has been shown to augment their cytotoxic activity (Goswami et al., 2018).”
BackgroundHeterogeneity and subtypes of CD4+ regulatory T cells: implications for tumor therapy
Lin, H., Xu, Y., & Lin, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1291796 · Cited by 15
Targeting Epigenetic Mechanisms: A Boon for Cancer Immunotherapy
Parab, A., Bhatt, L. K., & Omri, A. (2023) · Biomedicines · doi:10.3390/biomedicines11010169 · Cited by 13
Histone Modifications as Biomarkers for Immunotherapy
Taylor, E. M., Koss, B. S., Davis, L. E., & Tackett, A. J. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_10 · Cited by 13
Zhao, H., Liu, H., Kang, W., Zhan, C., Man, Y., & Qu, T. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01594-9 · Cited by 11
“For instance, it promoted the frequency of CD8 + T cells producing ifn γ and reduced inhibitory marker expression on tumor-infiltrating T cells [22].”
BackgroundPolycomb repressive complex 2 (PRC2) pathway’s role in cancer cell plasticity and drug resistance
Goleij, P., Heidari, M. M., Tabari, M. A. K., Hadipour, M., Rezaee, A., Javan, A., Sanaye, P. M., Larsen, D. S., Daglia, M., & Khan, H. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01563-8 · Cited by 17
“This suggests that dual inhibition of EZH2 and immune checkpoints could offer a potent therapeutic combination, particularly for tumors that are resistant to immunotherapy alone (Goswami et al. 2018a, b).”
InfluentialChen, Q., Chen, S., & Zhao, M. D. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s514881 · Cited by 15
“33 Downregulation of miR-200 promotes epithelial-mesenchymal transition (EMT), leading to reduced antigen presentation and immune escape.”
Metabolic regulation of the HBV-specific T cell function
Barili, V., Boni, C., Rossi, M., Vecchi, A. L., Zecca, A., Penna, A., Missale, G., Ferrari, C. I., & Fisicaro, P. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104989 · Cited by 13
Survivin prevents the polycomb repressor complex 2 from methylating histone 3 lysine 27
Jensen, M., Chandrasekaran, V., García-Bonete, M.-J., Li, S., Anindya, A. L., Andersson, K., Erlandsson, M. C., Oparina, N. Y., Burmann, B. M., Brath, U., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106976 · Cited by 11
Singh, R. K., Srivastava, P., & Manna, P. P. (2024) · Medical Oncology · doi:10.1007/s12032-023-02289-y · Cited by 12
“Pharmacologically altering T-cell EZH2 expression may enhance anti-CTLA-4-induced antitumor responses [101].”
Targeting the immune milieu in gastrointestinal cancers
Turkes, F., Mencel, J., & Starling, N. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01710-x · Cited by 11
Shi, M., Ding, X., Tang, L., Cao, W.-J., Su, B., & Zhang, J. (2024) · BMC Cancer · doi:10.1186/s12885-024-12244-3 · Cited by 12
“Currently, in several preclinical model studies, EZH2 inhibitors have been shown to enhance the effectiveness of immune checkpoint blockade (ICB) [51, 52] and have demonstrated the ability to overcome acquired resistance to ICB [53].”
BackgroundLuo, Y., Lu, J., Lei, Z., Zhu, H., Rao, D., Wang, T., Fu, C., Zhang, Z., Xia, L., & Huang, W. (2024) · Biomarker Research · doi:10.1186/s40364-024-00621-w · Cited by 13
“They suggested that inhibiting H3K27me3 in T cells using CPI-1205 could enhance the efficacy of anti-CTLA-4 therapy in bladder cancer and melanoma [192].”
BackgroundExtracellular Vesicles in Reprogramming of the Ewing Sarcoma Tumor Microenvironment
Pachva, M. C., Lai, H., Jia, A., Rouleau, M., & Sorensen, P. H. B. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.726205 · Cited by 13
Therapeutic opportunities to modulate immune tolerance through the metabolism-chromatin axis
Ferrara, A. L., Liotti, A., Pezone, A., & Rosa, V. D. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.04.002 · Cited by 10
Exploring the therapeutic potential of targeting polycomb repressive complex 2 in lung cancer
Gao, M., Li, Y., Cao, P., Liu, H., Chen, J., & Kang, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1216289 · Cited by 14
Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors
Karakashev, S. V., & Zhang, R. (2020) · Molecular & Cellular Oncology · doi:10.1080/23723556.2020.1760675 · Cited by 9
“It has been recently demonstrated that EZH2 inhibitors can also synergize with immune checkpoint blockers by activating immune cells directly as well as by decreasing the expression of PD-L1 receptor on the surface of cancer cells.(6) Similarly, PARP inhibitors have been also shown to potentiate the efficiency of immu…”
BackgroundEpigenetic Regulation of the Non-Coding Genome: Opportunities for Immuno-Oncology
Barrero, M. J. (2020) · Epigenomes · doi:10.3390/epigenomes4030022 · Cited by 10
Pyziak, K., Sroka‐Porada, A., Rzymski, T., Dulak, J., & Łoboda, A. (2021) · Drug Development Research · doi:10.1002/ddr.21796 · Cited by 10
Xueqing, X., Yongcan, P., Wei, L., Qingling, Y., & Jie, D. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24457 · Cited by 10
“In another study, genetic deletion of EZH2 in Tregs resulted in robust anti-tumor immunity in a mouse model [36].”
BackgroundEpigenetic mechanisms of liver tumor resistance to immunotherapy
Sanceau, J., & Gougèlet, A. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i9.979 · Cited by 10
Zhang, H., Huang, C. Y., Gordon, J. C., Yu, S., Morton, G. C., Childers, W. E., Abou-Gharbia, M. A., Zhang, Y., Jelínek, J., & Issa, J. J. (2024) · Clinical Epigenetics · doi:10.1186/s13148-023-01617-3 · Cited by 9
“Epi-genetic drugs may also target a variety type of immune cells, reduce generation and accumulation of myeloid-derived suppressor cells (MDSCs) [12], inhibit differentiation and function of Tregs [13–15], and increase production of effector T cell chemokines and activated effector T cells [16].”
BackgroundRegulatory T cells in cancer and inflammation
Yang, H., Zhang, H., Xia, N., & Cheng, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02584-w · Cited by 12
“…of Tregs to fragile Tregs; 74,309 altering the DNA hypomethylation status and histone acetylation status of Foxp3 can impact its transcription; 310,311 targeting metabolism-related molecules such as MCT-1 and CD36 can shift the metabolic state of Tregs in tumors, promoting an unstable…”
Mechanisms and measures to modulate T cell trafficking for amplified and tolerogenic immunity
Lu, Y., Liu, X., & You, J. (2023) · Nano Today · doi:10.1016/j.nantod.2023.102129 · Cited by 9
Transcriptional Control of Regulatory T Cells in Cancer: Toward Therapeutic Targeting?
Stéphan, P., Lautraite, R., Voisin, A., & Grinberg‐Bleyer, Y. (2020) · Cancers · doi:10.3390/cancers12113194 · Cited by 10
Can we use epigenetics to prime chemoresistant lymphomas?
Amengual, J. E. (2020) · Hematology · doi:10.1182/hematology.2020000092 · Cited by 8
Targeting EZH2 for the treatment of soft tissue sarcomas
Karolak, M., Tracy, I., SHIPLEY, J. M., & Walters, Z. S. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.05 · Cited by 8
Pharmacological Advancements of PRC2 in Cancer Therapy: A Narrative Review
Wang, M. S., Sussman, J., Xu, J.-J., Patel, R. T., Elghawy, O., & Rawla, P. (2024) · Life · doi:10.3390/life14121645 · Cited by 9
Metabolism and Immune Suppressive Response in Liver Cancer
Caini, P., & Carloni, V. (2025) · Biomedicines · doi:10.3390/biomedicines13061461 · Cited by 10
“Epigenetic modifications of NF-kB, STAT3, or HIF-1 α in cancer cells can enhance the production of cytokines and growth factors that favor macrophage recruitment, survival, and activation, further inhibiting immune responses [154–157].”
Huang, L., Xie, T., Zhao, F., Feng, Y., Zhu, H., Tang, L. M., Han, X., & Shi, Y. (2022) · Disease Markers · doi:10.1155/2022/6512300 · Cited by 8
“This study aimed to determine biomarkers associating with the remodeling of tumor microenvironment and predicting efficacy of ICIs therapy in patients with LUSC.”
BackgroundInfluentialEditorial: Epigenetic Regulation and Tumor Immunotherapy
Sun, H., Huang, B., Cao, J. P., Yan, Q., & Yin, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.893157 · Cited by 6
“Numerous preclinical and clinical studies revealed that epigenetic agents, including DNMT inhibitors (3), HDAC inhibitors (4), EZH2 inhibitors (5), LSD1 inhibitors (6), KDM5 inhibitors (7), G9a inhibitors (8), and BET inhibitors (9–11), have the capacity to induce anti-tumor immune responses and modulate tumor immune…”
BackgroundMegdiche, Y., & Salerno-Gonçalves, R. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1547213 · Cited by 9
“In melanoma and bladder cancer models, combining EZH2 inhibitors with anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) therapy demonstrated a direct role for EZH2-mediated T-cell reprogramming in enhancing anti-tumor immunity (54).”
Intracellular checkpoints for NK cell cancer immunotherapy
Huang, Y., Tian, Z., & Bi, J. (2024) · Frontiers of Medicine · doi:10.1007/s11684-024-1090-6 · Cited by 7
Role of EZH2 in bone marrow mesenchymal stem cells and immune–cancer interactions
Liu, Z., Jia, Y., Guo, Y., Wang, H., & Fu, R. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103547 · Cited by 7
New and Emerging Therapies in the Management of Bladder Cancer
Osterman, C. K., & Milowsky, M. I. (2020) · F1000Research · doi:10.12688/f1000research.26841.1 · Cited by 6
Fan, K., Zhang, C., Zhang, B.-H., Gao, M., & Sun, Y.-C. (2022) · Scientific Reports · doi:10.1038/s41598-022-21005-w · Cited by 6
Karamouzis, M. V., & Papavassiliou, A. G. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1494724 · Cited by 7
Unraveling the Epigenetic Regulation of Regulatory T Cells in Cancer Immunity
Subedi, K., Parajuli, N., Solone, X. K., Cruz, J., Kapur, S. K., Fang, D., Mi, Q., & Zhou, L. (2026) · Cells · doi:10.3390/cells15030228 · Cited by 5
“Moreover, preclinical studies combining EZH2 inhibitors (e.g., CPI-1205) with checkpoint blockade (anti-CTLA4) show synergistic effects: targeting EZH2 in Tregs enhances the efficacy of CTLA4 therapy without triggering systemic autoimmunity [294].”
CD4+ Regulatory T Cells in Human Cancer: Subsets, Origin, and Molecular Regulation
Swatler, J., Luca, M. D., Rotella, I., Lise, V., Mazza, E. M. C., & Lugli, E. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0517 · Cited by 6
Vlachostergios, P. J. (2021) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2021.100035 · Cited by 5
“EZH2) using small molecule inhibitors, such as CPI-1205, could improve antitumor responses elicited by anti-PD-1 or/and anti-CTLA-4 therapy.(33) Demethylating agents and histone deacetylases are currently being tested in combination with ICIs in numerous clinical trials and types of malignancies.”
BackgroundImpairment of regulatory T cell stability in axial spondyloarthritis: role of EZH2 and pSTAT5
Mebrek, M. L., Abaab, T., Lemeiter, D., Breckler, M., Hervé, R., Petit, M., Clavel, G., Sigaux, J., Boissier, M., Semerano, L., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1484321 · Cited by 4
Stairiker, C. J., Pfister, S. X., Hendrickson, E., Yang, W., Xie, T., Lee, C., Zhang, H., Dillon, C. P., Thomas, G. D., & Salek‐Ardakani, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.770080 · Cited by 4
“The efficacy is attributed to effects on cancer cells as EZH2i induce expression of antigen presentation-associated genes (8, 10) and chemokine ligands (9, 10).”
InfluentialThe functions of polycomb group proteins in T cells
Li, T. (2022) · Cell Insight · doi:10.1016/j.cellin.2022.100048 · Cited by 4
“Disruption of EZH2 activity in Treg cells, either pharmacologically or genetically, reprograms their phenotype to effector-like T cells, impairs Treg suppressive capacity, remodels the tumormicroenvironment, and leads to robust antitumor immunity (Goswami et al., 2018; Wang et al., 2018).”
BackgroundThe Heightened Importance of EZH2 in Cancer Immunotherapy
Lin, X., Zhou, W., Lin, C., & Cao, W. (2023) · Cancer Screening and Prevention · doi:10.14218/csp.2023.00006 · Cited by 7
Hsu, C., Mohammed, A. N., Hjazi, A. M., Uthirapathy, S., RenukaJyothi, S., Singh, A., Thyagarajan, Ray, S., & Hulail, H. M. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-03883-9 · Cited by 4
“Combination therapy using an EZH2 inhibitor could significantly increase the beneficial effects in animal models (Goswami et al. 2018).”
Targeting EZH2 in autoimmune diseases: unraveling epigenetic regulation and therapeutic potential
Harirah, H. A. A., Mohammed, M. H., Basha, S. A. Z., Uthirapathy, S., Ganesan, S., Shankhyan, A., Sharma, G. C., Devi, A., KADHIM, A. J., & Naher, H. S. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04127-6 · Cited by 4
“Blocking EZH2 production in Tregs can increase the activity against tumors brought through anti-CTLA-4 therapy, as demonstrated by the beneficial outcomes of EZH2 inhibitors and anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) cure (Goswami et al. 2018).”
Histone methylation modifiers in medical therapeutics
Trojer, P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823928-5.00020-7 · Cited by 5
The epigenetic regulation of the immune system during pregnancy
Liao, A., & Liu, H. Q. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818508-7.00005-1 · Cited by 3
Exploring the role of EZH2 modulation in shaping the tumor microenvironment
Fischetti, I., Michele, D. L., & Jachetti, E. (2024) · Epigenomics · doi:10.1080/17501911.2024.2410693 · Cited by 6
Metadata
- Authors
- Goswami, S., Apostolou, I., Zhang, J., Skepner, J., Anandhan, S., Zhang, X., Xiong, L., Trojer, P., Aparicio, A., Subudhi, S. K., Allison, J. P., Zhao, H., & Sharma, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Constellation Pharmaceuticals (United States) (US)
- Corresponding author
- Sharma, Padmanee
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2018-07-30
- Volume
- 128
- Issue
- 9
- Pages
- 3813-3818
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6118570
- OpenAlex
- W2807710457
- Cited by
- 244
- References
- 22
- Citations by year
- 2026: 16 · 2025: 28 · 2024: 37 · 2023: 25 · 2022: 28 · 2021: 46 · 2020: 41 · 2019: 21 · 2018: 2
- FWCI
- 10.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Parker Institute for Cancer Immunotherapy, National Institutes of Health (R01CA163793)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- EZH2, epigenetic regulation, CTLA-4, ipilimumab, CTLA-4 blockade, regulatory T cells, Foxp3, EZH2 inhibition, antitumor immunity, T cell immunity, combination immunotherapy, tumor immunology
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, Antineoplastic Agents, Immunological, Ipilimumab, Animals, Enzyme Inhibitors, Humans, Indoles, Mice, Inbred C57BL, Mice, Transgenic, Neoplasms, Experimental, Piperidines, Cell Line, Tumor, T-Lymphocytes, Regulatory, Mice, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.